KEAP1 and cancer: ,81,83,86 Across pan-cancer analyses, while KEAP1 mutations were enriched in KRAS G12C tumors (15.38% vs. 4.61% in non-G12C), this pattern was less pronounced in NSCLC-specific contexts, likely attributable to overlapping mutational landscapes and tissue-specific selection pressures.4